past
decad
excit
progress
made
field
nanotechnolog
mani
research
group
studi
wide
varieti
nanomateri
differ
compon
size
shape
surfac
characterist
applic
field
medicin
chemistri
pharmaceut
applic
nanotechnolog
vaccin
deliveri
particular
interest
treatment
mani
infecti
diseas
hiv
aid
mani
limit
advers
effect
classic
vaccin
strategi
use
live
kill
microb
one
altern
classic
approach
peptidebas
subunit
vaccin
peptid
antigen
use
main
vaccin
compon
even
though
antigen
weak
compar
tradit
vaccin
use
whole
pathogen
addit
adjuv
often
requir
antigen
size
molecular
weight
length
identifi
affect
efficaci
vaccin
small
peptid
antigen
gener
weakli
immunogen
administr
without
adjuv
formul
nanoparticlebas
peptid
vaccin
aim
increas
size
vaccin
compon
antigen
molecul
similar
pathogen
bacteria
virus
nanoparticl
also
act
immun
adjuv
small
peptid
antigen
envelop
nanocontain
coval
attach
molecul
ntermin
amino
group
ctermin
carboxyl
group
variou
side
chain
function
group
use
nanoparticl
overcom
limit
peptidebas
vaccin
nanoparticl
protect
encapsul
attach
peptid
enzymat
degrad
deliv
peptid
antigen
immun
cell
henc
classifi
nanoparticlebas
peptid
vaccin
approach
two
strategi
noncoval
attachmententrap
short
peptid
antigen
nanoparticl
coval
conjug
short
peptid
antigen
surfac
nanoparticl
platform
former
type
antigen
contain
emuls
liposom
virosom
immunestimul
complex
iscom
antigen
contain
also
construct
wellcharacter
nanopolym
exampl
poli
lacticcoglycol
acid
plga
synthet
copolym
compos
lactid
glycolid
biodegrad
biocompat
materi
approv
us
food
drug
administr
fda
european
medicin
agenc
ema
use
microand
nanoparticlebas
drug
deliveri
devic
human
use
nanoparticl
encapsul
bioactiv
compound
previous
describ
detail
chapter
focu
current
statu
latter
strategi
involv
present
multipl
copi
peptid
antigen
coval
attach
surfac
nanoparticl
construct
variou
materi
nanoparticlebas
vaccin
prepar
preconstruct
nanos
platform
follow
attach
antigen
chemic
modif
peptid
antigen
prior
formul
nanoparticl
tradit
attenu
kill
pathogenbas
vaccin
prepar
whole
microorgan
virus
bacteria
contain
wide
varieti
protein
receptor
enzym
act
antigen
gener
vaccin
use
whole
microb
elicit
strong
immun
respons
often
lifelong
protect
without
need
boost
immun
howev
use
liveattenu
vaccin
risk
infect
remain
one
exampl
develop
vaccineassoci
paralyt
poliomyel
vaccinederiv
poliovirus
case
live
oral
polio
vaccin
strain
polioviru
oral
polio
vaccin
may
undergo
occasion
genet
chang
caus
paralysi
million
dose
vaccin
anoth
limit
use
live
kill
microb
human
vaccin
potenti
harm
effect
includ
toxic
immun
crossreact
human
tissu
whole
microorgan
use
vaccin
constitu
must
kept
mind
also
contain
lipid
nucleotid
lipid
compon
gramneg
bacteria
lipopolysaccharid
lpss
deriv
salmonella
minnesota
escherichia
coli
bind
tolllik
receptor
express
surfac
varieti
cell
dendrit
cell
dc
respons
endotox
shock
addit
certain
dna
rna
fragment
deriv
infecti
microb
bind
type
tlr
rna
fragment
also
act
sirna
influenc
host
immun
system
posit
neg
manner
certain
sirna
activ
host
innat
immun
rnaimedi
type
interferon
induct
use
potenti
therapeut
tool
howev
may
caus
gene
silenc
follow
downregul
molecul
associ
host
immun
respons
cytokin
cluster
differenti
antigen
protein
isol
recombin
deriv
infecti
microb
could
potenti
candid
subunit
vaccin
howev
immunogen
protein
alon
weaker
compar
tradit
attenu
inactiv
pathogen
vaccin
gener
everi
protein
sever
epitop
b
cell
th
ctl
epitop
may
induc
suffici
immun
respons
vaccin
purpos
howev
risk
develop
allergi
crossreact
host
tissu
still
need
consid
instanc
surfac
protein
group
streptococci
ga
strongli
immunogen
major
virul
factor
ga
infect
indic
potenti
target
ga
vaccin
develop
howev
immun
protein
may
elicit
crossreact
human
heart
muscl
addit
ntermin
region
protein
hypervari
consequ
differ
serotyp
identifi
far
issu
make
difficult
develop
broadli
protect
ga
vaccin
base
protein
use
welldefin
peptid
epitop
exclud
biocompon
microb
ideal
approach
develop
safe
vaccin
term
minim
risk
side
effect
elicit
desir
immun
respons
contrari
advantag
immun
short
synthet
peptid
epitop
alon
unabl
stimul
strong
immun
respons
anim
pharmaceut
develop
includ
addit
chemic
modif
util
carrier
protein
adjuv
vaccin
formul
antigen
deliveri
system
essenti
size
immunogen
one
import
factor
vaccin
efficaci
size
comparison
differ
vaccin
compon
illustr
fig
gener
human
cell
includ
immun
cell
differ
size
rang
sever
hundr
micromet
exampl
among
antigenpres
cell
apc
human
immun
system
macrophag
averag
size
matur
dc
averag
diamet
immatur
dc
even
smaller
matur
dc
infecti
pathogen
microscop
bacteria
show
wide
divers
shape
size
usual
anywher
length
exampl
rodshap
e
coli
width
approxim
length
contrast
virus
rang
size
nm
diamet
influenza
viru
exampl
approxim
nm
size
protein
much
smaller
virus
antibodi
averag
molecular
weight
kda
length
nm
ovalbumin
ova
one
studi
antigen
compos
amino
acid
molecular
weight
kda
molecular
diamet
nm
peptid
antigen
use
vaccin
studi
compos
singl
b
cell
epitop
ctl
epitop
th
cell
epitop
rel
longer
peptid
contain
differ
epitop
like
ova
peptid
b
cell
th
cell
epitop
sequenc
although
actual
size
depend
fold
linear
peptid
compos
ten
amino
acid
approxim
size
one
nanomet
mention
previous
decreas
size
immunogen
trim
antigen
protein
minim
epitop
reduc
risk
side
effect
also
affect
vaccin
efficaci
nanoparticl
appli
peptid
subunit
vaccin
develop
recov
lost
immunogen
safe
peptid
epitop
sever
studi
investig
differ
particl
size
peptid
vaccin
particl
vaccin
formul
need
size
similar
pathogen
order
taken
apc
nanoparticl
size
virus
rang
ten
hundr
nanomet
microparticl
similar
bigger
size
bacteria
base
surfacevolum
ratio
smaller
nanoparticl
wider
surfac
area
attach
absorpt
peptid
antigen
larger
microparticl
wherea
encapsul
bigger
particl
suitabl
load
larger
amount
antigen
peptid
easili
entrap
encapsul
nanovehicl
attach
onto
nanoparticl
surfac
comparison
protein
due
smaller
size
moreov
smaller
particl
reach
blood
lymph
node
larger
particl
remain
inject
site
smallers
particl
taken
receptormedi
endocytosi
contrast
largers
particl
taken
phagocytosi
micropinocytosi
dc
macrophag
prefer
smallers
particl
largers
particl
respect
plebanski
group
studi
sizedepend
immunogen
nanobeadsantigen
conjug
use
commerci
avail
carboxyl
polystyren
rang
differ
size
size
conjug
use
nanobead
show
strongest
immun
respons
thu
particl
sizedepend
immunostimulatori
effect
signific
design
particlebas
vaccin
elicit
desir
immun
respons
howev
composit
particl
also
import
factor
kirbi
et
al
studi
vaccin
efficaci
two
type
plgabas
microparticl
prepar
materi
similar
size
first
formul
oilinwat
singl
emuls
absorb
antigen
surfac
second
waterinoilinwat
doubl
emuls
entrap
antigen
within
particl
amount
load
protein
antigen
oilinwat
singl
emuls
system
approxim
three
time
larger
waterinoilinwat
doubl
emuls
system
releas
antigen
oilinwat
singl
emuls
show
notabl
burst
releas
first
h
mice
immun
two
type
particl
show
signific
differ
immun
respons
oilinwat
singl
emuls
absorb
antigen
system
promot
humor
respons
waterinoilinwat
doubl
emuls
entrap
antigen
promot
cellular
respons
find
indic
antigen
dosag
immun
respons
depend
particl
type
well
chemic
synthesi
peptid
protein
regard
develop
protect
group
coupl
method
significantli
progress
sinc
studi
curtiu
fischer
earli
centuri
develop
solid
phase
peptid
synthesi
spp
merrifield
nativ
chemic
ligat
techniqu
kent
cowork
well
recent
applic
microwav
irradi
spp
improv
coupl
efficaci
reaction
time
reduct
byproduct
especi
synthesi
longer
peptid
chemic
peptid
synthesi
current
carri
larg
scale
allow
product
gram
even
kilogram
peptid
peptid
store
ship
lyophil
powder
protein
gener
labil
cold
chain
often
requir
maintain
immunolog
properti
anoth
advantag
protein
structur
sequenc
synthet
peptid
arbitrarili
modifi
demand
follow
manner
natur
protein
peptid
typic
linear
backbon
synthet
peptid
design
linear
form
also
branch
cyclic
form
ly
residu
exampl
two
amino
group
modifi
creat
branch
peptid
backbon
lysbas
dendrit
scaffold
use
multipl
antigen
peptid
map
system
cycliz
peptid
affect
secondari
structur
relev
biolog
activ
case
eg
b
cell
epitop
need
maintain
nativ
conform
trigger
desir
humor
immun
headtotail
cycliz
avoid
peptid
hydrolysi
exoact
enzym
due
absenc
nand
ctermini
nonproteinogen
amino
acid
includ
damino
acid
acid
well
artifici
amino
acid
lipoamino
acid
readili
introduc
peptid
epitop
spp
gener
addit
andor
substitut
noncod
amino
acid
render
peptid
reduc
suscept
enzymat
degrad
amino
acid
deriv
lipophil
modif
bacteri
lipid
compon
ligand
heterodim
heterodim
respect
immun
bacteri
synthet
peptid
antigen
contain
elicit
strong
immun
respons
matur
dc
via
activ
tlr
ligandantigen
conjug
vaccin
approach
enhanc
immun
respons
review
elsewher
peptid
protein
sever
function
group
side
chain
hydroxyl
group
ser
thr
tyr
amino
group
ly
thiol
group
cy
group
physiolog
target
posttransl
modif
eg
lipid
glycosyl
phosphoryl
disulfid
bond
format
modif
affect
solubl
fold
biolog
activ
includ
immun
respons
peptid
protein
case
difficult
express
recombin
protein
desir
posttransl
modif
howev
spp
achiev
faith
reproduct
sitespecif
mimick
peptid
fragment
deriv
natur
modifi
protein
bacteri
lipoproteinspeptid
glycoproteinspeptid
lipophil
modif
similar
addit
mention
earlier
carri
attach
long
alkyl
chain
peptid
epitop
result
lipopeptid
show
amphiphil
properti
enhanc
immunogen
compar
peptid
antigen
without
lipid
chain
regard
glycosyl
tumorassoci
carbohydr
link
protein
highli
overexpress
tumor
cell
compar
express
almost
epitheli
tissu
glycosyl
tumor
cell
consider
differ
normal
cell
tumorassoci
carbohydr
antigen
taca
includ
tn
antigen
sialyl
tn
stn
antigen
attract
target
develop
anticanc
vaccin
taca
empir
shown
elicit
weak
immun
respons
without
coval
attach
carrier
protein
th
cell
epitop
via
peptid
chemistri
peptidebas
vaccin
readili
synthes
taca
singl
construct
dc
mannos
receptor
eg
human
mannos
receptor
uptak
mannosyl
protein
antigen
deriv
bacteria
fungi
one
import
featur
dc
mannos
receptormedi
uptak
antigen
enhanc
hla
class
iirestrict
antigen
present
therefor
mannos
receptor
surfac
dc
attract
target
develop
new
antigen
deliveri
system
immun
mannosyl
ovalbumin
peptid
manova
show
enhanc
antigen
present
induc
prolifer
cell
studi
human
papillomaviru
hpv
associ
cervic
cancer
attach
mannos
moieti
nterminu
peptid
epitop
deriv
hpv
protein
effici
reduc
tumor
size
mice
compar
nonmannosyl
peptid
furthermor
spp
varieti
function
group
ad
either
ntermin
amino
group
side
chainfunct
group
fig
order
conjug
peptid
epitop
molecul
epitop
carrier
protein
micronanoparticl
even
cycliz
peptid
chemoselect
ligat
method
exampl
thiol
addit
maleimid
thiol
group
thioether
ligat
haloacetyl
group
thiol
group
copper
catalyz
azidealkyn
cycloaddit
cuaac
huisgen
reaction
oxim
ligat
aldehyd
cho
group
hydroxylamin
nh
group
hydrazon
ligat
aldehyd
group
hydrazin
nh
nh
group
fig
experiment
proven
immunogen
antigen
short
peptid
polysaccharid
enhanc
coadministr
coval
conjug
carrier
protein
tetanu
toxoid
tt
diphtheria
toxoid
dt
keyhol
limpet
hemocyanin
klh
ova
bovin
serum
albumin
bsa
carrier
protein
act
sourc
th
cell
epitop
also
increas
molecular
size
antigen
therebi
facilit
uptak
immun
cell
macrophag
dc
antigen
size
play
import
role
elicit
immun
respons
howev
carrier
protein
caus
undesir
effect
suppress
antipeptid
antibodi
product
product
antibodi
carrier
protein
local
reaction
eg
extens
red
swell
case
excess
dose
toxoid
vaccin
dt
tt
tam
demonstr
synthet
peptid
use
multipleantigenpres
platform
altern
approach
call
multipl
antigen
peptid
map
system
shown
fig
copi
short
peptid
epitop
amino
acid
residu
simultan
attach
group
lysbas
dendrim
result
proteins
singl
molecul
present
multipl
peptid
epitop
copi
importantli
lysbas
dendrit
scaffold
nonimmunogen
immun
map
vaccin
candid
mice
rabbit
success
elicit
stronger
antibodi
product
compar
correspond
peptid
monom
peptid
epitopecarri
protein
conjug
tam
lysbas
dendrim
first
artifici
platform
use
develop
multipl
antigenpres
vaccin
open
new
way
vaccin
design
overcom
weak
immunogen
short
peptid
assembl
multipl
copi
peptid
epitop
lysbas
dendrim
use
convent
stepwis
spp
often
affect
problem
associ
purif
final
product
use
purifi
wellcharacter
short
peptid
epitop
fragment
condens
one
fundament
solut
obtain
highli
pure
homogen
product
bear
multipl
copi
peptid
antigen
linear
cyclic
peptid
scaffold
multival
function
group
develop
multipleantigenpres
platform
peptid
vaccin
also
carbohydr
vaccin
carbohydr
multipl
hydroxyl
group
function
group
modifi
coval
attach
multipl
antigen
copi
free
radicalinduc
polymer
acryloyl
ch
chco
group
yield
linear
alkan
polym
acryloyl
peptid
epitop
homolog
heterolog
epitop
convert
larg
immunogen
bear
hundr
epitop
attach
alkan
backbon
jackson
et
al
evalu
vaccin
efficaci
polymer
immunogen
contain
eight
differ
epitop
deriv
ga
protein
polymer
ga
vaccin
molecul
show
outstand
broad
immunogen
protect
ga
infect
mice
antibodi
individu
epitop
present
polym
success
elicit
recent
multipl
copi
purifi
peptid
epitop
coval
attach
synthet
dendrim
via
click
chemistri
cuaac
conjug
selfassembl
nanoparticl
nm
capabl
induc
strong
antibodi
product
also
sizedepend
respons
report
conjug
show
smaller
nanoparticl
induc
stronger
humor
immun
plebanski
group
studi
conjug
commerci
avail
carboxyl
polystyren
nanobead
nm
peptid
epitop
deriv
ova
viral
protein
vp
capsid
protein
footandmouth
diseas
viru
fmdv
vaccin
nanobead
conjug
either
cell
epitop
deriv
ova
b
cell
epitop
fmdv
show
induct
cell
antibodi
respons
inhibit
tumor
growth
inorgan
materi
also
known
form
nanoparticl
attract
scaffold
nanoparticlebas
vaccin
colloid
gold
nanoparticl
gnp
ideal
purpos
primarili
biocompat
lack
immunogen
easili
prepar
gold
salt
h
aucl
water
particl
size
control
within
nano
rang
peptid
contain
cy
readili
conjug
surfac
gnp
via
thiol
group
result
present
multipl
peptid
gnp
surfac
chen
et
al
studi
immunolog
efficaci
nanos
nm
diamet
gnpepitop
conjug
contain
epitop
deriv
protein
fmdv
extra
cy
residu
provid
thiol
function
conjug
conjug
use
midsiz
nanoparticl
nm
show
stronger
antibodi
product
compar
size
particl
klh
carrier
protein
conjug
midsiz
particl
nm
also
show
highest
level
biodistribut
spleen
tao
et
al
studi
stabil
peptidegold
nanoparticl
conjug
lyophil
dri
powder
lyophil
bare
gold
nanoparticl
exhibit
aggreg
could
resuspend
contrast
lyophil
peptidegold
conjug
uniformli
resuspend
water
aggreg
conjug
peptid
onto
gold
nanoparticl
lead
increas
stabil
reproduc
conjug
potenti
advantag
storag
solid
form
follow
lyophil
furthermor
addit
cpg
ligand
adjuv
conjug
disturb
stabil
colloid
suspens
lipopeptid
produc
bacteria
fungi
virus
wide
varieti
biolog
activ
includ
antimicrobi
activ
due
lipid
tail
attach
hydrophil
peptid
lipopeptid
amphiphil
physicochem
properti
lipid
chain
peptid
caus
selfassembl
nanoparticl
micel
fibril
core
compos
lipid
moieti
high
densiti
peptid
epitop
orient
outward
shown
fig
lipopeptid
build
block
aggreg
nanoparticl
present
multipl
peptid
antigen
copi
lipophil
modif
peptid
antigen
studi
field
vaccin
develop
year
date
sever
lipophil
moieti
success
use
fig
ntermin
part
lipopeptid
deriv
inner
outer
membran
compon
gramneg
bacteria
lipid
compon
macrophageactiv
lipopeptid
isol
mycoplasma
amino
acid
deriv
exampl
oacyl
serin
npalmitoyl
lysin
lipoamino
acid
laa
util
lipophil
modif
fig
discoveri
tlr
famili
mechan
lipopeptid
vaccin
thought
base
abil
lipopeptid
attach
membran
apc
intern
cytoplasm
thought
promot
mhc
class
iii
present
induc
cytokin
secret
discoveri
human
tlr
famili
reveal
ligand
heterodim
respect
tlr
activ
trigger
innat
immun
system
respons
activ
nfkb
signal
pathway
lipopeptid
induc
humor
cellular
immun
respons
attach
peptid
antigen
without
addit
adjuv
carrier
protein
cocryst
structur
heterodim
obtain
recent
aid
modern
adjuv
develop
sever
structureact
relationship
studi
deriv
report
metzger
et
al
report
chiral
glyceryl
unit
strongli
affect
adjuv
efficaci
rconfigur
glyceryl
unit
prefer
bioactiv
form
reichel
et
al
studi
physicochem
relationship
stereochemistri
selfassembl
properti
use
transmiss
electron
microscopi
tem
varieti
shape
vesicl
layer
fibril
tubular
network
differ
size
rang
nm
observ
indic
chiral
glyceryl
unit
addit
serin
residu
exert
influenc
mode
aggreg
monolay
properti
hamley
et
al
investig
selfassembl
properti
amphiphil
lipopeptid
pamcysserlyslyslysli
pamci
npalmitoylcystein
use
cd
spectrum
smallangl
xray
scatter
cryogen
tem
found
number
acyl
chain
peptid
terminu
influenc
secondari
structur
nanostructur
lipopeptid
adopt
structur
selfassembl
wormlik
micel
thick
nm
two
peptid
form
spheric
micel
diamet
smaller
nm
wilkinson
et
al
studi
anticanc
lipopeptid
vaccin
three
th
epitop
padr
tumorassoci
antigen
vntr
domain
form
contain
tumorassoci
carbohydr
antigenswer
coval
conjug
expect
tricompon
vaccin
molecul
found
selfassembl
nanos
particl
averag
size
nm
administr
tricompon
vaccin
mice
induc
strong
humor
immun
respons
includ
product
isotyp
skew
respons
isotyp
anticarbohydr
antibodi
toth
colleagu
investig
lipoamino
acid
laa
differ
length
alkyl
chain
purpos
synthet
lipopeptid
subunit
vaccin
ga
infect
hookworm
infect
schistosoma
mansoni
infect
anticanc
vaccin
elong
peptid
epitop
coupl
sever
copi
laa
enhanc
antibodi
product
attach
epitop
without
addit
adjuv
structur
arrang
epitop
b
cell
epitop
th
cell
epitop
lipid
moieti
singl
design
molecul
influenc
induct
immunolog
respons
lipid
moieti
compos
synthet
laa
activ
recent
studi
investig
amphipath
charact
lipopeptid
compos
b
cell
epitop
cell
epitop
lipid
moieti
show
form
nanos
particl
pb
doubl
copi
laa
tend
lead
format
larger
particl
mean
size
nanoparticl
may
control
number
laa
residu
well
length
laa
alkyl
chain
accardo
cowork
studi
amphiphil
peptid
vaccin
herp
simplex
viru
hsv
n
ndioctadecylsuccinam
acid
lipid
unit
chemic
conjug
epitop
deriv
hsv
envelop
glycoprotein
b
via
linker
result
lipopeptid
aggreg
micel
hydrodynam
radii
nm
micel
trigger
human
mous
macrophag
cell
releas
higher
level
cytokin
particular
compar
correspond
singl
epitop
without
lipid
moieti
tirrel
group
investig
lipopeptid
vaccin
use
dipalmityl
ester
glutam
acid
dic
lipoid
moieti
shown
fig
dic
unit
attach
ctermini
peptid
ovalbumin
ctl
epitop
ova
b
cell
epitop
deriv
ga
protein
tem
atom
forc
microscop
afm
measur
show
amphiphil
dic
ova
selfassembl
cylindr
micel
approxim
nm
diamet
nm
length
unlik
lipopeptid
dic
ova
induc
stimul
subcutan
immun
dic
ova
micel
effici
activ
mhc
present
ctl
immun
respons
result
reduct
tumor
size
lipopeptid
micel
compos
dic
moieti
b
cell
epitop
abl
elicit
antibodi
product
without
adjuv
inject
mice
find
underscor
consider
relev
selfassembl
lipopeptid
system
antigen
deliveri
devic
induct
desir
immun
respons
certain
peptid
sequenc
adopt
secondari
structur
selfassembl
aqueou
solut
subsequ
form
nanoparticl
via
noncoval
interact
eg
hydrogen
bond
electrostat
interact
van
der
waal
bond
stack
interact
peptid
also
call
selfassembl
peptid
recent
selfassembl
peptid
attract
lot
attent
topolog
defin
build
block
date
number
selfassembl
peptid
sequenc
develop
chemic
physic
biolog
properti
well
applic
field
medicin
chemistri
pharmaceut
includ
drug
deliveri
report
applic
vaccin
deliveri
peptidebas
nanovaccin
particular
interest
theoret
elong
selfassembl
peptid
sequenc
onto
peptid
epitop
without
linker
yield
singl
antigen
molecul
subsequ
assembl
nanos
particl
present
multipl
repetit
copi
given
epitop
high
densiti
shown
fig
polyglutamin
polyq
domain
found
sever
type
aggregationpron
protein
associ
neurodegener
eg
huntington
diseas
short
polyq
domain
qs
solubl
longer
polyq
domain
qs
tend
aggreg
ilyinski
et
al
investig
model
fusion
protein
polyq
domain
longer
glutamin
residu
attach
weak
immunogen
green
fluoresc
protein
gfp
use
plasmid
dna
vaccin
polyqassoci
aggreg
express
antigen
strongli
enhanc
antibodi
cytotox
respons
gfp
mice
immun
suggest
linkag
elong
polyq
domain
antigen
potenc
adjuv
peptid
abl
adopt
coiledcoil
conform
tend
aggreg
fiber
burkhard
et
al
studi
selfassembl
peptidebas
nanoparticl
consist
pentamer
coiledcoil
oligomer
domain
deriv
cartilag
oligomer
matrix
protein
comp
de
novo
design
trimer
coiledcoil
sequenc
subsequ
appli
design
multipl
antigenpres
vaccin
selfassembl
peptid
conjug
ctermin
heptad
repeat
region
epitop
deriv
sever
acut
respiratori
syndrom
coronaviru
sarscov
protein
b
cell
epitop
form
nanoparticl
nm
size
multipl
copi
epitop
surfac
immunolog
evalu
conjug
contain
sar
epitop
show
product
specif
antibodi
neutral
activ
sarscov
infect
build
block
use
selfassembl
peptidebas
vaccin
malaria
conjug
b
cell
epitop
dppppnpn
deriv
circumsporozoit
protein
malaria
parasit
plasmodium
berghei
selfassembl
nanoparticl
nm
diamet
conjug
contain
malaria
epitop
elicit
high
level
antibodi
product
immun
mice
immun
mice
show
longlast
protect
parasit
month
selfassembl
peptidebas
nanosystem
also
use
develop
hiv
vaccin
antitumor
vaccin
peptid
compos
selfassembl
sequenc
epitop
assembl
nanos
fiber
present
multipl
epitop
copi
system
discuss
previous
use
larg
recombin
polypeptidesprotein
longer
amino
acid
collier
colleagu
util
short
fibril
peptid
qqkfqfqfeqq
develop
biomateri
biomedicin
assembl
salti
aqueou
solut
form
network
nanofib
width
nm
importantli
appear
nonantigen
coadministr
strong
adjuv
complet
freund
adjuv
cfa
mice
induc
antibodi
product
peptid
gel
consid
multipl
antigendisplay
platform
selfassembl
peptid
vaccin
peptid
contain
b
cell
cell
epitop
sequenc
deriv
chicken
egg
ova
conjug
nterminu
via
short
linker
sergli
conjug
assembl
nanos
fiber
subcutan
administr
mice
success
induc
strong
antiova
antibodi
product
absenc
addit
adjuv
antibodi
titer
remark
higher
compar
mixtur
ova
epitop
cfa
without
inflamm
inject
site
furthermor
studi
peptid
vaccin
continu
prophylact
vaccin
epitop
conjug
also
cancer
therapeut
vaccin
conjug
tumorassoci
antigen
addit
collier
group
also
report
use
anoth
selfassembl
sequenc
fkfefkf
antigen
coadministr
cfa
conjug
also
form
nanofib
abl
success
induc
ovaspecif
antibodi
product
show
anoth
potenti
antigendisplay
platform
recent
toth
group
investig
applic
synergist
effect
fibril
peptid
lipid
moieti
selfassembl
peptidebas
subunit
nanovaccin
synthes
peptid
compos
b
cell
epitop
deriv
ga
protein
andor
lipid
moieti
singl
doubl
copi
laa
acid
peptid
form
nanoparticl
nm
howev
visibl
fibril
network
format
predomin
observ
tem
cd
spectra
measur
respect
among
five
test
peptid
contain
doubl
copi
show
better
result
regard
cellular
uptak
antibodi
product
compar
peptid
assum
failur
fibril
format
lead
loss
adjuv
activ
selfassembl
peptid
strategi
breakthrough
develop
peptidebas
subunit
nanovaccin
notabl
short
peptid
sequenc
ffi
deriv
form
nanofibr
hydrogel
use
deliveri
system
recent
appli
studi
plasmid
dna
vaccin
howev
short
selfassembl
peptid
use
peptidebas
vaccin
yet
predict
new
design
combin
selfassembl
peptid
nanomateri
peptid
epitopeseith
b
cell
epitop
th
cell
epitop
ctl
epitopesha
great
potenti
creat
peptidebas
nanovaccin
induc
suitabl
longterm
immun
respons
without
side
effect
great
effort
undertaken
improv
antigen
short
peptid
effici
stimul
suitabl
immun
evok
adapt
immun
avoid
side
effect
use
differ
type
nanomateri
current
number
approv
vaccin
adjuvantdeliveri
system
human
use
limit
develop
nanotechnolog
spark
remark
progress
nanoparticlebas
vaccin
develop
includ
use
immun
adjuv
antigen
deliveri
system
aim
slow
control
releas
allow
singleinject
vaccin
formul
even
needlefre
mucos
vaccin
ultim
goal
improv
qualiti
life
peopl
applic
welldefin
nanoparticl
peptidebas
subunit
vaccin
offer
mani
advantag
signific
potenti
develop
nextgener
vaccin
manufactur
preserv
perspect
highli
pure
synthet
peptid
antigen
contain
selfassembl
sequenc
lipid
moieti
except
interest
easili
produc
spp
lyophil
amorph
form
suitabl
stabl
storag
medic
use
furthermor
peptid
capabl
selfassembl
form
nanoparticl
whenev
requir
anim
immun
studi
alreadi
demonstr
util
nanoparticlebas
peptid
subunit
vaccin
induct
desir
immun
respons
cytokin
product
recruit
lymphocyt
cellular
andor
humor
respons
howev
despit
enorm
amount
studi
correl
nanomateri
properti
eg
size
shape
biolog
effect
eg
immunogen
toxic
issu
safeti
still
need
address
increas
technic
invent
abil
analyz
immunolog
phenomena
aid
obtain
purposedesign
formul
optim
prophylact
therapeut
vaccin
